3.34
Precedente Chiudi:
$3.33
Aprire:
$3.34
Volume 24 ore:
158.38K
Relative Volume:
0.37
Capitalizzazione di mercato:
$145.22M
Reddito:
-
Utile/perdita netta:
$-110.66M
Rapporto P/E:
-1.0787
EPS:
-3.0963
Flusso di cassa netto:
$-97.76M
1 W Prestazione:
-6.30%
1M Prestazione:
+31.18%
6M Prestazione:
+11.50%
1 anno Prestazione:
-52.08%
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KYTX
Kyverna Therapeutics Inc
|
3.36 | 147.38M | 0 | -110.66M | -97.76M | -3.0963 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
376.61 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.84 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
428.47 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
668.81 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2024-10-10 | Iniziato | UBS | Buy |
2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
2024-03-04 | Iniziato | JP Morgan | Overweight |
2024-03-04 | Iniziato | Leerink Partners | Outperform |
2024-03-04 | Iniziato | Morgan Stanley | Overweight |
2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $15.60 Average Target Price from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Monday - MarketBeat
What are analysts’ price targets for Kyverna Therapeutics Inc. in the next 12 monthsInvest confidently with data-driven strategies - Jammu Links News
What is the risk reward ratio of investing in Kyverna Therapeutics Inc. stockInvest confidently with expert support - Jammu Links News
How does Kyverna Therapeutics Inc. generate profit in a changing economyUnlock real-time stock alerts for quick profits - Jammu Links News
What are the latest earnings results for Kyverna Therapeutics Inc.Expert guidance for superior capital growth - Jammu Links News
What analysts say about Kyverna Therapeutics Inc. stockCapital growth strategies that work - Jammu Links News
Is Kyverna Therapeutics Inc. a growth stock or a value stockAchieve superior capital gains with smart trades - Jammu Links News
What institutional investors are buying Kyverna Therapeutics Inc. stockGet expert advice on portfolio optimization - Jammu Links News
What are Kyverna Therapeutics Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Does Kyverna Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Kyverna Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Is it the right time to buy Kyverna Therapeutics Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
How volatile is Kyverna Therapeutics Inc. stock compared to the marketDynamic profit expansion - Jammu Links News
What catalysts could drive Kyverna Therapeutics Inc. stock higher in 2025High-profit capital plays - Jammu Links News
Should I hold or sell Kyverna Therapeutics Inc. stock in 2025Maximize gains with professional stock picks - jammulinksnews.com
How strong is Kyverna Therapeutics Inc. company’s balance sheetStock Strategy Recommendation From AI Tools - Jammu Links News
Is Kyverna Therapeutics Inc. stock overvalued or undervaluedPost Market Guidance For Smart Trading - jammulinksnews.com
Exit strategy if you’re trapped in Kyverna Therapeutics Inc.Short Term Setup With Predictive Chart Confirmed - metal.it
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionKYTX - ACCESS Newswire
Analysts Apply Wyckoff Model to Kyverna Therapeutics Inc. StockPattern Detection for Entry Confirmation Enabled - beatles.ru
Trendlines Suggest Kyverna Therapeutics Inc. May Bottom Out SoonWeekly Return Pick Forecast Reports Show Trend - metal.it
Rising Star: Covington's Alicia Zhang - Law360
Kyverna Appoints New CFO to Guide Next Growth Phase - Insider Monkey
Kyverna Therapeutics to Host Virtual KOL Event on Neuroimmunology CAR T Franchise - AInvest
Leading Neurologists Reveal Game-Changing CAR T Treatment for Rare Autoimmune Disorders - Stock Titan
Published on: 2025-07-29 14:03:16 - metal.it
What does KYTX's flat EPS in 2024 indicate for investors? - AInvest
11 Best New Penny Stocks to Buy Right Now - Insider Monkey
What institutions are buying Kyverna Therapeutics Inc. stock nowDaily Smart Money Movement Monitor Activated - metal.it
Why did Kyverna's operating expenses surge in Q4 2024? - AInvest
How many analysts rate Kyverna Therapeutics Inc. as a “Buy”Breakout Stocks Strategy With Low Risk - jammulinksnews.com
Why is Kyverna Therapeutics Inc. stock attracting strong analyst attentionBest Dividend Tips From AI Tools - Jammu Links News
Published on: 2025-07-28 19:09:23 - metal.it
What is the dividend policy of Kyverna Therapeutics Inc. stockAchieve breakthrough gains with smart trades - Jammu Links News
Will Kyverna Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsHigh Return Investment Tips - Newser
Published on: 2025-07-27 18:04:27 - Jammu Links News
How Kyverna Therapeutics Inc. stock performs during market volatilityFree Access to Investment Community - Newser
Why Kyverna Therapeutics Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):